See more : i-CABLE Communications Limited (1097.HK) Income Statement Analysis – Financial Results
Complete financial analysis of ImmunoGen, Inc. (IMGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ImmunoGen, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Asia Polymer Corporation (1308.TW) Income Statement Analysis – Financial Results
- Lehar Footwears Limited (LEHAR.BO) Income Statement Analysis – Financial Results
- Storm Exploration Inc. (CWVWF) Income Statement Analysis – Financial Results
- Shandong Longquan Pipeline Engineering Co.,LTD (002671.SZ) Income Statement Analysis – Financial Results
- Munters Group AB (publ) (MMNNF) Income Statement Analysis – Financial Results
ImmunoGen, Inc. (IMGN)
About ImmunoGen, Inc.
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 108.78M | 108.78M | 132.30M | 82.27M | 53.82M | 115.45M | 48.63M | 60.00M | 85.54M | 59.90M | 35.54M | 16.36M | 19.31M | 13.94M | 27.99M | 40.25M | 38.21M | 32.09M | 35.72M | 25.96M | 7.63M | 5.88M | 4.48M | 11.18M | 3.70M | 600.00K | 400.00K | 500.00K | 500.00K | 900.00K | 1.70M | 2.70M | 3.40M | 1.00M | 800.00K |
| Cost of Revenue | 176.00K | 176.00K | 114.59M | 114.52M | 173.89M | 139.74M | 141.31M | 146.92M | 111.77M | 106.96M | 87.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.57M | 2.67M | 9.24M | 5.66M | 2.83M | 3.34M | 597.05K | -463.45K | -500.00K | -1.10M | -1.50M | -6.00M | 13.40M | 17.90M | -1.70M | -1.30M | 9.50M | 7.10M | 4.70M |
| Gross Profit | 108.61M | 108.61M | 17.71M | -32.25M | -120.07M | -24.29M | -92.68M | -86.91M | -26.23M | -47.06M | -51.54M | 16.36M | 19.31M | 13.94M | 27.99M | 40.25M | 34.64M | 29.42M | 26.48M | 20.30M | 4.79M | 2.54M | 3.88M | 11.64M | 4.20M | 1.70M | 1.90M | 6.50M | -12.90M | -17.00M | 3.40M | 4.00M | -6.10M | -6.10M | -3.90M |
| Gross Profit Ratio | 99.84% | 99.84% | 13.38% | -39.20% | -223.11% | -21.04% | -190.60% | -144.85% | -30.66% | -78.57% | -145.03% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 90.65% | 91.69% | 74.14% | 78.20% | 62.84% | 43.21% | 86.67% | 104.15% | 113.51% | 283.33% | 475.00% | 1,300.00% | -2,580.00% | -1,888.89% | 200.00% | 148.15% | -179.41% | -610.00% | -487.50% |
| Research & Development | 213.37M | 213.37M | 114.59M | 114.52M | 173.89M | 139.74M | 141.31M | 146.92M | 111.77M | 106.96M | 87.07M | 69.19M | 63.45M | 50.28M | 45.90M | 60.01M | 45.84M | 40.91M | 30.54M | 22.22M | 23.43M | 17.69M | 15.21M | 8.88M | 6.10M | 6.60M | 7.40M | 9.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 43.81M | 38.60M | 38.49M | 36.72M | 33.91M | 38.53M | 36.92M | 28.23M | 24.47M | 21.47M | 20.42M | 16.04M | 14.90M | 13.90M | 14.35M | 11.03M | 9.90M | 8.77M | 6.63M | 5.96M | 5.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 72.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 116.13M | 116.13M | 38.60M | 38.49M | 36.72M | 33.91M | 38.53M | 36.92M | 28.23M | 24.47M | 21.47M | 20.42M | 16.04M | 14.90M | 13.90M | 14.35M | 11.03M | 9.90M | 8.77M | 6.63M | 5.96M | 5.40M | 4.48M | 3.06M | 1.80M | 1.70M | 2.20M | 1.80M | 3.00M | 4.50M | 20.20M | 18.00M | 1.40M | 1.40M | 1.00M |
| Other Expenses | 3.35M | 3.35M | 1.21M | 5.01M | 3.33M | 2.61M | 0.00 | 304.00K | -848.00K | 167.00K | 198.00K | 64.68M | 56.20M | 44.92M | 38.34M | 44.98M | 23.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 463.45K | 500.00K | 1.10M | 1.50M | 6.00M | 3.40M | 2.00M | 1.70M | 1.30M | 1.10M | 700.00K | 300.00K |
| Operating Expenses | 329.50M | 329.50M | 153.19M | 153.01M | 210.60M | 173.65M | 43.54M | 183.83M | 140.00M | 131.43M | 108.54M | 89.61M | 79.49M | 65.18M | 59.80M | 74.36M | 56.87M | 50.81M | 39.30M | 28.86M | 29.39M | 23.10M | 19.69M | 12.40M | 8.40M | 9.40M | 11.10M | 17.40M | 6.40M | 6.50M | 21.90M | 19.30M | 2.50M | 2.10M | 1.30M |
| Cost & Expenses | 329.68M | 329.68M | 153.19M | 153.01M | 210.60M | 173.65M | 184.85M | 183.83M | 140.00M | 131.43M | 108.54M | 89.61M | 79.49M | 65.18M | 59.80M | 74.36M | 60.44M | 53.47M | 48.54M | 34.51M | 32.22M | 26.44M | 20.29M | 11.94M | 7.90M | 8.30M | 9.60M | 11.40M | 19.80M | 24.40M | 20.20M | 18.00M | 12.00M | 9.20M | 6.00M |
| Interest Income | 4.34M | 51.00K | 729.00K | 4.42M | 0.00 | 0.00 | 20.51M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 4.17M | 4.17M | 23.20M | 16.97M | 10.73M | 16.72M | 0.00 | 20.13M | 5.44M | 0.00 | 0.00 | 62.00K | 0.00 | 0.00 | 221.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 3.35M | -1.08M | 115.80M | 26.45M | 7.41M | 5.96M | 6.01M | 5.33M | 5.51M | 4.60M | 4.64M | 4.63M | 4.94M | 4.84M | 5.00M | 3.93M | 3.15M | 2.69M | 2.22M | 1.29M | 1.13M | 984.76K | 612.82K | 463.45K | 500.00K | 1.10M | 1.50M | 6.00M | 3.40M | 2.00M | 1.70M | 1.30M | 1.10M | 700.00K | 300.00K |
| EBITDA | -217.55M | -217.55M | -19.68M | -65.73M | -153.45M | -55.60M | -125.20M | -123.53M | -55.30M | -71.53M | -73.01M | -73.20M | -62.10M | -51.29M | -31.60M | -32.30M | -22.35M | -18.99M | -10.53M | -8.59M | -25.42M | -20.57M | -15.66M | -366.61K | -3.80M | -6.60M | -7.90M | -3.00M | -15.90M | -21.50M | -16.80M | -14.00M | -7.50M | -7.50M | -4.90M |
| EBITDA Ratio | -199.98% | -199.98% | -14.88% | -79.89% | -285.15% | -48.16% | -257.46% | -205.87% | -64.65% | -119.43% | -205.46% | -447.48% | -321.69% | -367.88% | -112.89% | -80.25% | -58.48% | -59.19% | -29.47% | -33.09% | -333.30% | -349.63% | -349.69% | -3.28% | -102.70% | -1,100.00% | -1,975.00% | -600.00% | -3,180.00% | -2,388.89% | -988.24% | -518.52% | -220.59% | -750.00% | -612.50% |
| Operating Income | -220.89M | -220.89M | -135.49M | -92.17M | -160.48M | -58.98M | -131.21M | -123.83M | -54.46M | -71.53M | -73.01M | -73.26M | -60.19M | -51.24M | -31.82M | -34.11M | -22.23M | -21.39M | -12.82M | -8.56M | -24.59M | -20.56M | -15.81M | -761.00K | -4.20M | -7.70M | -9.20M | -10.90M | -19.30M | -23.50M | -18.50M | -15.30M | -8.60M | -8.20M | -5.20M |
| Operating Income Ratio | -203.06% | -203.06% | -102.41% | -112.04% | -298.20% | -51.09% | -269.83% | -206.37% | -63.66% | -119.43% | -205.46% | -447.86% | -311.77% | -367.46% | -113.68% | -84.75% | -58.16% | -66.65% | -35.90% | -32.97% | -322.39% | -349.41% | -353.01% | -6.81% | -113.51% | -1,283.33% | -2,300.00% | -2,180.00% | -3,860.00% | -2,611.11% | -1,088.24% | -566.67% | -252.94% | -820.00% | -650.00% |
| Total Other Income/Expenses | -818.00K | -14.23M | -21.99M | -11.96M | -8.36M | -37.03M | -25.52M | -19.83M | -6.28M | 167.00K | 198.00K | -62.00K | 1.91M | 58.00K | -221.00K | 2.12M | 3.27M | 3.57M | 1.90M | 2.69M | 4.65M | 6.05M | 6.34M | 523.44K | 100.00K | 100.00K | 200.00K | -5.60M | -600.00K | -200.00K | -100.00K | 0.00 | -100.00K | -100.00K | -100.00K |
| Income Before Tax | -221.71M | -221.71M | -44.37M | -104.13M | -167.87M | -96.01M | -156.73M | -143.66M | -60.74M | -71.36M | -72.81M | -73.32M | -58.27M | -51.18M | -32.04M | -31.99M | -18.95M | -17.82M | -10.92M | -5.87M | -19.95M | -14.50M | -9.47M | -237.56K | -4.10M | -7.60M | -9.00M | -16.50M | -19.90M | -23.70M | -18.60M | -15.30M | -8.70M | -8.30M | -5.30M |
| Income Before Tax Ratio | -203.81% | -203.81% | -33.54% | -126.57% | -311.94% | -83.17% | -322.31% | -239.42% | -71.01% | -119.15% | -204.90% | -448.24% | -301.86% | -367.04% | -114.47% | -79.49% | -49.60% | -55.53% | -30.58% | -22.62% | -261.49% | -246.51% | -211.49% | -2.12% | -110.81% | -1,266.67% | -2,250.00% | -3,300.00% | -3,980.00% | -2,633.33% | -1,094.12% | -566.67% | -255.88% | -830.00% | -662.50% |
| Income Tax Expense | 1.22M | 1.22M | 22.31M | 17.96M | 7.39M | 37.03M | 0.00 | 19.83M | 6.28M | -167.00K | -198.00K | 62.00K | -1.91M | -265.00K | -100.00K | 27.00K | 35.00K | 17.00K | 29.00K | 45.49K | 35.13K | 127.81K | 82.60K | 237.56K | 4.10M | 7.60M | 9.00M | 16.50M | 19.90M | 23.70M | 18.60M | 15.30M | 100.00K | 8.30M | 5.30M |
| Net Income | -222.93M | -222.93M | -66.68M | -122.09M | -167.87M | -96.01M | -156.73M | -143.66M | -60.74M | -71.36M | -72.81M | -73.32M | -58.27M | -50.91M | -31.94M | -32.02M | -18.99M | -17.83M | -10.95M | -5.92M | -19.98M | -14.63M | -15.29M | -237.56K | -4.10M | -7.60M | -9.00M | -16.50M | -19.90M | -23.70M | -18.60M | -15.30M | -8.80M | -8.30M | -5.30M |
| Net Income Ratio | -204.93% | -204.93% | -50.40% | -148.40% | -311.94% | -83.17% | -322.31% | -239.42% | -71.01% | -119.15% | -204.90% | -448.24% | -301.86% | -365.14% | -114.11% | -79.55% | -49.69% | -55.58% | -30.66% | -22.80% | -261.95% | -248.68% | -341.36% | -2.12% | -110.81% | -1,266.67% | -2,250.00% | -3,300.00% | -3,980.00% | -2,633.33% | -1,094.12% | -566.67% | -258.82% | -830.00% | -662.50% |
| EPS | -0.88 | -0.88 | -0.38 | -0.82 | -1.20 | -0.98 | -1.80 | -1.65 | -0.71 | -0.83 | -0.87 | -0.95 | -0.85 | -0.87 | -0.63 | -0.75 | -0.45 | -0.43 | -0.27 | -0.15 | -0.48 | -0.37 | -0.42 | -0.01 | -0.16 | -0.31 | -0.50 | -1.32 | -1.58 | -2.09 | -1.76 | -1.58 | -1.28 | -1.46 | -3.36 |
| EPS Diluted | -0.88 | -0.88 | -0.38 | -0.82 | -1.20 | -0.98 | -1.80 | -1.65 | -0.71 | -0.83 | -0.87 | -0.95 | -0.85 | -0.87 | -0.63 | -0.75 | -0.45 | -0.43 | -0.27 | -0.15 | -0.48 | -0.37 | -0.42 | -0.01 | -0.16 | -0.31 | -0.50 | -1.32 | -1.58 | -2.09 | -1.76 | -1.58 | -1.28 | -1.46 | -3.36 |
| Weighted Avg Shares Out | 253.33M | 253.63M | 176.15M | 148.31M | 139.95M | 98.07M | 87.08M | 86.98M | 86.04M | 85.48M | 84.06M | 76.81M | 68.92M | 58.85M | 51.07M | 42.97M | 41.76M | 41.18M | 40.87M | 40.65M | 41.91M | 39.62M | 36.68M | 29.52M | 25.53M | 24.21M | 17.86M | 12.50M | 12.57M | 11.34M | 10.57M | 9.68M | 6.88M | 5.68M | 1.58M |
| Weighted Avg Shares Out (Dil) | 253.63M | 253.63M | 176.15M | 148.31M | 139.95M | 98.07M | 87.08M | 86.98M | 86.04M | 85.48M | 84.06M | 76.81M | 68.92M | 58.85M | 51.07M | 42.97M | 41.76M | 41.18M | 40.87M | 40.65M | 41.91M | 39.62M | 36.68M | 32.85M | 25.53M | 24.21M | 17.86M | 12.50M | 12.62M | 11.34M | 10.57M | 9.68M | 6.88M | 5.68M | 1.58M |
AbbVie Cuts Its Guidance on ImmunoGen Deal
Drug maker AbbVie (ABBV) is lowering its current quarter guidance because of costs related to its acquisition of ImmunoGen.
AbbVie's stock dips premarket after it lowers Q1 guidance to reflect dilutive impact of ImmunoGen deal close
AbbVie Inc.'s stock ABBV, -0.41% fell 0.5% early Monday, after the drug company lowered its first-quarter guidance to reflect the dilutive impact of its closure of the acquisition of ImmunoGen. The company said it now expects first-quarter per-share earnings to...
AbbVie Completes Acquisition of ImmunoGen
Adds flagship antibody-drug conjugate (ADC) ELAHERE® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio ImmunoGen's pipeline complements AbbVie's existing oncology pipeline with potential to be transformative across multiple solid tumors and hematologic malignancies ImmunoGen's...
Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?
Here is how ImmunoGen (IMGN) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.
ImmunoGen (IMGN) Soars 5.7%: Is Further Upside Left in the Stock?
ImmunoGen (IMGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024
As 2023 wrapped up, Russell 2000 stocks, mirroring the dynamics of small-to-mid-cap companies, showed resilience, outperforming their initial stance. The iShares Russell 2000 ETF (NYSEARCA: IWM ), a key barometer for these stocks, boasts over $60 billion in assets and...
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
How ImmunoGen (IMGN) Stock Stands Out in a Strong Industry
ImmunoGen (IMGN) has seen solid earnings estimate revision activity over the past two month, and belongs to a strong industry as well.
Cramer names biopharma companies to watch as industry mergers start to pile up
CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.
All You Need to Know About ImmunoGen (IMGN) Rating Upgrade to Strong Buy
ImmunoGen (IMGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Source: https://incomestatements.info
Category: Stock Reports